ADAM-17激活EGFR信号通路介导大肠癌化疗耐药及肠胃清对其作用的研究

本课题旨在探讨差异表达的ADAM-17对人结肠癌奥沙利铂（L-OHP）耐药细胞HCT116/L-OHP凋亡作用的影响。通过分子克隆的方法构建靶向ADAM-17基因的siRNA质粒, 转染HCT116/L-OHP耐药细胞，检测细胞内ADAM-17的表达，进一步验证ADAM-17在结肠癌耐药细胞凋亡通路中的可能作用机制。观察中药复方肠胃清（CWQ）含药血清对ADAM-17/EGFR凋亡通路的影响，阐明中药复方肠胃清逆转人结肠癌奥沙利铂耐药的分子机制，探索ADAM-17与肿瘤耐药的相关机制，为指导临床应用中医药增加肿瘤细胞化疗敏感性的作用机制提供了新的研究思路和实验依据。

To investigate the differently expression of ADAM-17 effect on cell apoptosis.human colon cancer resistant cell HCT116/L-OHP to oxaliplatin(L-OHP).Construct targeted ADAM-17 gene Small interfering RNA (siRNA) plasmid, transfection HCT116/L-OHP resistant cells using molecular cloning methods, the detection of intracellular expression of ADAM-17 , further verification the possible mechanism of drug-resistant colon cancer cell apoptosis pathway . Observe the effect of compound Changweiqing（CWQ） containing serum of ADAM-17/EGFR apoptosis pathway , to elucidate the molecular mechanisms of resistance of traditional Chinese medicine CWQ reversal of human colon cancer oxaliplatin explore ADAM-17 and cancer drug resistance mechanisms , for the mechanism provides a new research ideas and experimental evidence to clarify the clinical Chinese medicine to increase tumor cell sensitivity to chemotherapy.